DE3019350A1 - Neue derivate der 3-aminopropansulfonsaeure mit verstaerkten membranstabilisierenden eigenschaften - Google Patents
Neue derivate der 3-aminopropansulfonsaeure mit verstaerkten membranstabilisierenden eigenschaftenInfo
- Publication number
- DE3019350A1 DE3019350A1 DE19803019350 DE3019350A DE3019350A1 DE 3019350 A1 DE3019350 A1 DE 3019350A1 DE 19803019350 DE19803019350 DE 19803019350 DE 3019350 A DE3019350 A DE 3019350A DE 3019350 A1 DE3019350 A1 DE 3019350A1
- Authority
- DE
- Germany
- Prior art keywords
- acetylhomotaurinate
- namely
- derivative according
- solution
- magnesium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000936 membranestabilizing effect Effects 0.000 title description 4
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 21
- 239000011777 magnesium Substances 0.000 claims description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 229910052749 magnesium Inorganic materials 0.000 claims description 16
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical class NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 claims description 13
- 239000011734 sodium Substances 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- 229910052708 sodium Inorganic materials 0.000 claims description 12
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 229910052700 potassium Inorganic materials 0.000 claims description 10
- 239000011591 potassium Substances 0.000 claims description 10
- 229910052744 lithium Inorganic materials 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- BUVGWDNTAWHSKI-UHFFFAOYSA-L acamprosate calcium Chemical compound [Ca+2].CC(=O)NCCCS([O-])(=O)=O.CC(=O)NCCCS([O-])(=O)=O BUVGWDNTAWHSKI-UHFFFAOYSA-L 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 2
- 150000007530 organic bases Chemical class 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 20
- 239000000243 solution Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010010904 Convulsion Diseases 0.000 description 6
- 230000008485 antagonism Effects 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- 230000036461 convulsion Effects 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000007912 intraperitoneal administration Methods 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- CXJAAWRLVGAKDV-UHFFFAOYSA-N acetyltaurine Chemical class CC(=O)NCCS(O)(=O)=O CXJAAWRLVGAKDV-UHFFFAOYSA-N 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 4
- 230000035873 hypermotility Effects 0.000 description 4
- 229960003080 taurine Drugs 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 3
- 229960004047 acamprosate Drugs 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 230000000875 corresponding effect Effects 0.000 description 3
- 230000008588 hemolysis Effects 0.000 description 3
- 230000000087 stabilizing effect Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910003002 lithium salt Inorganic materials 0.000 description 2
- 159000000002 lithium salts Chemical class 0.000 description 2
- 159000000003 magnesium salts Chemical class 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical group 0.000 description 1
- OBESRABRARNZJB-UHFFFAOYSA-N aminomethanesulfonic acid Chemical compound NCS(O)(=O)=O OBESRABRARNZJB-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 239000003076 neurotropic agent Substances 0.000 description 1
- 230000002276 neurotropic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- -1 papaverine Chemical class 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940072033 potash Drugs 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Inorganic materials [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- XJLMLOAYGUOMDM-UHFFFAOYSA-M sodium;3-acetamidopropane-1-sulfonate Chemical compound [Na+].CC(=O)NCCCS([O-])(=O)=O XJLMLOAYGUOMDM-UHFFFAOYSA-M 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/13—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton
- C07C309/14—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton
- C07C309/15—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing nitrogen atoms, not being part of nitro or nitroso groups, bound to the carbon skeleton containing amino groups bound to the carbon skeleton the nitrogen atom of at least one of the amino groups being part of any of the groups, X being a hetero atom, Y being any atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7913207A FR2457281A1 (fr) | 1979-05-23 | 1979-05-23 | Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE3019350A1 true DE3019350A1 (de) | 1980-12-04 |
| DE3019350C2 DE3019350C2 (enrdf_load_stackoverflow) | 1989-11-30 |
Family
ID=9225819
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1996175017 Active DE19675017I2 (de) | 1979-05-23 | 1980-05-21 | Neue Derivate der 3-Aminopropansulfonsaeure diese enthaltende Arzneimittel sowie Verfahren zu ihrer Herstellung |
| DE19803019350 Granted DE3019350A1 (de) | 1979-05-23 | 1980-05-21 | Neue derivate der 3-aminopropansulfonsaeure mit verstaerkten membranstabilisierenden eigenschaften |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1996175017 Active DE19675017I2 (de) | 1979-05-23 | 1980-05-21 | Neue Derivate der 3-Aminopropansulfonsaeure diese enthaltende Arzneimittel sowie Verfahren zu ihrer Herstellung |
Country Status (18)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102008048791A1 (de) | 2008-09-24 | 2010-03-25 | Merck Patent Gmbh | Neue Kristallform von Calcium-3-Acetylaminopropan-1-sulfonat |
| US7994218B2 (en) | 2007-09-07 | 2011-08-09 | Xenoport, Inc. | Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU193197B (en) * | 1984-02-03 | 1987-08-28 | Egyt Gyogyszervegyeszeti Gyar | Preparatives regulating the growth of plants containing as reagent derivatives of n-substituated amin-prophansulphonic acid and process for production of the reagent |
| JPH0725771B2 (ja) * | 1992-06-18 | 1995-03-22 | 財団法人生産開発科学研究所 | ２−アミノエタンスルホン酸亜鉛錯化合物 |
| US20040208875A1 (en) * | 1995-03-15 | 2004-10-21 | Queen's University At Kingston | Method for treating amyloidosis |
| AU703540B2 (en) * | 1996-03-26 | 1999-03-25 | Meddiss, Incorporated | Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general |
| US6057373A (en) * | 1997-05-22 | 2000-05-02 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders using NMDA receptor antagonists |
| US5952389A (en) * | 1998-01-13 | 1999-09-14 | Synchroneuron | Methods of treating tardive dyskinesia and other movement disorders |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| AU765522B2 (en) * | 1998-01-13 | 2003-09-18 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US6265437B1 (en) * | 1998-01-27 | 2001-07-24 | Lipha | Aminoalkanesulphonic acid derivatives, their preparation and their use as medicaments |
| US20020022657A1 (en) * | 1998-02-11 | 2002-02-21 | Francine Gervais | Methods for modulating neuronal cell death |
| FR2775188B1 (fr) * | 1998-02-23 | 2001-03-09 | Lipha | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
| NZ543319A (en) * | 1999-04-28 | 2007-06-29 | Neurochem Int Ltd | Compositions and methods for treating amyloidosis using sulphonate derivatives |
| US6562836B1 (en) | 1999-05-24 | 2003-05-13 | Queen's University Of Kingston | Methods and compounds for inhibiting amyloid deposits |
| US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US7414076B2 (en) * | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| MX2007005507A (es) * | 2004-11-12 | 2008-03-13 | Neurochem Int Ltd | Metodos y composiciones fluoradas para el tratamiento de padecimientos relacionados con amiloides. |
| WO2006059245A2 (en) * | 2004-11-16 | 2006-06-08 | Neurochem (International) Limited | Compounds for the treatment of cns and amyloid associated diseases |
| AU2005326962A1 (en) | 2004-12-22 | 2006-08-17 | Bellus Health (International) Limited | Methods and compositions for treating amyloid-related diseases |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| WO2007125385A2 (en) * | 2005-12-22 | 2007-11-08 | Neurochem (International) Limited | Treatment of renal disorders, diabetic nephopathy and dyslipidemias |
| EP2862581B1 (en) | 2006-10-12 | 2021-08-11 | BHI Limited Partnership | Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid |
| AU2007337806A1 (en) * | 2006-12-22 | 2008-07-03 | Bellus Health (International) Limited | Methods, compounds, and compositions for treating metabolic disorders and diabetes |
| KR100877134B1 (ko) * | 2007-05-03 | 2009-01-09 | 주식회사 엔지켐 | 아캄프로세이트 칼슘의 제조방법 |
| US20090082464A1 (en) * | 2007-09-07 | 2009-03-26 | Bernd Jandeleit | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| TW200932734A (en) * | 2007-10-15 | 2009-08-01 | Xenoport Inc | Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| CN101492400B (zh) * | 2008-01-22 | 2014-03-12 | 北京华禧联合科技发展有限公司 | 一种高纯度阿坎酸钙的制备方法 |
| IT1392327B1 (it) * | 2008-09-26 | 2012-02-28 | Laboratorio Chimico Int Spa | Nuova forma polimorfa del calcio acamprosato |
| CN104478766A (zh) * | 2014-12-25 | 2015-04-01 | 北京华禧联合科技发展有限公司 | 一种制备高纯度乙酰基高牛磺酸的方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2321285A1 (fr) * | 1975-08-18 | 1977-03-18 | Stanley Drug Products Inc | Agents antifibrinolytiques |
| FR2384751A1 (fr) * | 1977-03-23 | 1978-10-20 | Francaise Coop Pharma | Nouveaux derives de la taurine a activite neuro-musculaire renforcee |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3039916A (en) * | 1961-03-27 | 1962-06-19 | West Laboratories Inc | Anionic iodine complexes |
| US3544597A (en) * | 1969-06-12 | 1970-12-01 | Rohm & Haas | Process for manufacturing sulfonated amides |
| JPS5418714B2 (enrdf_load_stackoverflow) * | 1974-10-08 | 1979-07-10 | ||
| US4233229A (en) * | 1978-01-03 | 1980-11-11 | Gaf Corporation | Preparation of salt-free N-acyl taurines |
-
1979
- 1979-05-23 FR FR7913207A patent/FR2457281A1/fr active Granted
-
1980
- 1980-05-19 US US06/150,946 patent/US4355043A/en not_active Expired - Lifetime
- 1980-05-20 GR GR62000A patent/GR68547B/el unknown
- 1980-05-21 DE DE1996175017 patent/DE19675017I2/de active Active
- 1980-05-21 DE DE19803019350 patent/DE3019350A1/de active Granted
- 1980-05-22 GB GB8016956A patent/GB2051789B/en not_active Expired
- 1980-05-22 CH CH3998/80A patent/CH647757A5/fr not_active IP Right Cessation
- 1980-05-22 AT AT0274580A patent/AT372371B/de not_active IP Right Cessation
- 1980-05-22 MA MA19051A patent/MA18855A1/fr unknown
- 1980-05-22 ZA ZA00803051A patent/ZA803051B/xx unknown
- 1980-05-22 IT IT67807/80A patent/IT1130455B/it active
- 1980-05-23 JP JP6796380A patent/JPS5625146A/ja active Granted
- 1980-05-23 CA CA000352613A patent/CA1152100A/en not_active Expired
- 1980-05-23 OA OA57119A patent/OA06606A/xx unknown
- 1980-05-23 BE BE0/200755A patent/BE883468A/fr not_active IP Right Cessation
- 1980-05-23 ES ES491787A patent/ES8101042A1/es not_active Expired
- 1980-05-23 NL NL8002997A patent/NL191789C/xx not_active IP Right Cessation
- 1980-05-23 AU AU58697/80A patent/AU535785B2/en not_active Expired
-
1990
- 1990-10-17 JP JP2276598A patent/JPH03148219A/ja active Granted
-
1992
- 1992-06-25 MX MX9203363A patent/MX9203363A/es unknown
-
1997
- 1997-01-22 NL NL970003C patent/NL970003I2/nl unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2321285A1 (fr) * | 1975-08-18 | 1977-03-18 | Stanley Drug Products Inc | Agents antifibrinolytiques |
| FR2384751A1 (fr) * | 1977-03-23 | 1978-10-20 | Francaise Coop Pharma | Nouveaux derives de la taurine a activite neuro-musculaire renforcee |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994218B2 (en) | 2007-09-07 | 2011-08-09 | Xenoport, Inc. | Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US8168617B2 (en) | 2007-09-07 | 2012-05-01 | Xenoport, Inc. | Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| DE102008048791A1 (de) | 2008-09-24 | 2010-03-25 | Merck Patent Gmbh | Neue Kristallform von Calcium-3-Acetylaminopropan-1-sulfonat |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3019350A1 (de) | Neue derivate der 3-aminopropansulfonsaeure mit verstaerkten membranstabilisierenden eigenschaften | |
| DE69104723T2 (de) | Hustenstillendes und schleimregulierendes mittel, verfahren zu seiner herstellung und dieses enthaltende pharmazeutische zusammensetzungen. | |
| DE1445154C3 (de) | 1,4-Dihydro-1,8-naphthyridinderi vate und ein Verfahren zu ihrer Herstellung | |
| DE2810918C2 (de) | Taurin-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2065635C3 (de) | 10-Dioxo-11 -methyldibenzothiazepinderivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen | |
| DE1795792A1 (de) | Die serumlipoidkonzentration vermindernde arzneimittel | |
| DE3152071C2 (de) | Taurinderivate, deren Herstellung und Verwendung in Arzneimitteln | |
| DE2103387C3 (de) | Verwendung des Hydrochlorids von Glukosamin zur Herstellung von pharmazeutischen Präparaten | |
| DE68903059T2 (de) | Strontiumsalz, verfahren zu dessen herstellung und arzneimittel, die es enthalten. | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege | |
| DE2641388C3 (de) | 3',4'-Didesoxykanamycin B-N-methansulfonsäuren und deren Alkalimetallsalze sowie diese Verbindungen enthaltende pharmazeutische Präparate | |
| CH624098A5 (enrdf_load_stackoverflow) | ||
| CH635102A5 (de) | Verfahren zur herstellung neuer heterocyclischer verbindungen. | |
| DE2513136C3 (de) | N-(1-Benzylpiperid-4-yl)-benzamide, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate | |
| DE2530515C2 (de) | 4- bzw. 7-Hydroxy-4,5,6,7-tetrahydrothieno-[3,2-c] bzw.[2,3-c] pyridine, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittelzubereitungen | |
| DE2416339B2 (de) | Argininpyroglutamat, Verfahren zu seiner Herstellung und Arzneimittel | |
| DE2835987A1 (de) | 3-amino-17a-aza-d-homo-5 alpha -androstanderivate und quaternaere salze davon sowie verfahren zu ihrer herstellung | |
| DE2911377C3 (de) | 3-Hydroxy-4-hydroxymethyl-phenylglycin (Forphenicinol), dessen Hydrate und Salze, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2357320C3 (de) | 3-Metnyl-8-methoxy-(3H)-l,2,5.6tetrahydropyrazino- [1,23-ab] - ß -carbolin, seine Salze sowie ein Verfahren zu deren Herstellung und Arzneimittel | |
| DE2227846A1 (de) | Phenoxyessigsaeure-derivate und verfahren zu ihrer herstellung | |
| DE2036633A1 (de) | Arzneimittel mit entzündungshemmender, analgetischer und antipyretischer Wirksam | |
| DE2406849C3 (de) | Nicotinsäure-trans-3,3,5-trimethylcyclohex-1-yl-ester, Verfahren zu seiner Herstellung und diesen Ester enthaltendes Arzneimittel | |
| DE3320145C2 (de) | Verfahren zur Herstellung von Magnesiumdihydroorotatglycinaten und ihre Verwendung als Calcium-Antagonisten | |
| DE954726C (de) | Verfahren zur Herstellung von Komplexverbindungen des Calciums | |
| DE2542154A1 (de) | 6-aryloxy-2-oxo-1-aza-oxa (oder -thia) -spiro eckige klammer auf 4,5 eckige klammer zu -decane, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition | ||
| V448 | Application of spc |
Free format text: PRODUCT NAME: ACAMPROSAT - CALCIUM; REGISTRATION NO/DATE: 34384.00.00, 19951211 Spc suppl protection certif: 196 75 017 Filing date: 19960607 |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: LIPHA LYONNAISE INDUSTRIELLE PHARMACEUTIQUE S.A., |
|
| 8328 | Change in the person/name/address of the agent |
Free format text: SCHUETTLER, R., DIPL.-CHEM.DR.RER.NAT., PAT.-ASS., 6100 DARMSTADT |
|
| V457 | Spc granted |
Free format text: PRODUCT NAME: ACAMPROSAT - CALCIUM; REGISTRATION NO/DATE: 34384.00.00, 19951211 Spc suppl protection certif: 196 75 017 Filing date: 19960607 |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: LIPHA, LYON, FR |
|
| V464 | Spc expired |
Free format text: PRODUCT NAME: ACAMPROSAT - CALCIUM; REGISTRATION NO/DATE: 34384.00.00, 19951211 Spc suppl protection certif: 196 75 017 Filing date: 19960607 |